Voyager Therapeutics (VYGR) Given a $25.00 Price Target at HC Wainwright

HC Wainwright set a $25.00 price objective on Voyager Therapeutics (NASDAQ:VYGR) in a report released on Friday morning, The Fly reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. ValuEngine raised shares of Voyager Therapeutics from a hold rating to a buy rating in a report on Tuesday. BidaskClub upgraded Voyager Therapeutics from a hold rating to a buy rating in a research report on Saturday, August 25th. BTIG Research reiterated a buy rating and set a $32.00 price target on shares of Voyager Therapeutics in a research report on Monday, September 10th. Canaccord Genuity reiterated a buy rating and set a $31.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, July 17th. Finally, Morgan Stanley cut Voyager Therapeutics from an overweight rating to an equal rating in a research report on Monday, September 10th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Voyager Therapeutics has a consensus rating of Buy and an average target price of $28.00.

NASDAQ VYGR traded up $0.01 during trading on Friday, hitting $12.32. 464,491 shares of the company’s stock traded hands, compared to its average volume of 303,780. The company has a market cap of $453.78 million, a PE ratio of -4.67 and a beta of 3.15. Voyager Therapeutics has a 12-month low of $11.00 and a 12-month high of $31.91.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.15. The business had revenue of $2.09 million for the quarter, compared to the consensus estimate of $3.02 million. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 73.99%. As a group, equities research analysts expect that Voyager Therapeutics will post -2.87 EPS for the current fiscal year.

In related news, Director James A. Geraghty acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were bought at an average cost of $19.39 per share, for a total transaction of $58,170.00. Following the completion of the transaction, the director now owns 76,588 shares in the company, valued at $1,485,041.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Glenn Pierce acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The stock was bought at an average price of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 11,000 shares of company stock worth $205,300. Company insiders own 33.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY increased its position in shares of Voyager Therapeutics by 53.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock worth $177,000 after purchasing an additional 3,157 shares during the last quarter. MetLife Investment Advisors LLC increased its position in shares of Voyager Therapeutics by 38.6% in the second quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock worth $208,000 after purchasing an additional 2,964 shares during the last quarter. Thompson Davis & CO. Inc. increased its position in shares of Voyager Therapeutics by 187.9% in the second quarter. Thompson Davis & CO. Inc. now owns 11,951 shares of the company’s stock worth $234,000 after purchasing an additional 7,800 shares during the last quarter. Hershey Trust Co. bought a new position in shares of Voyager Therapeutics in the second quarter worth approximately $284,000. Finally, Commonwealth Equity Services LLC increased its position in shares of Voyager Therapeutics by 27.4% in the second quarter. Commonwealth Equity Services LLC now owns 16,272 shares of the company’s stock worth $318,000 after purchasing an additional 3,500 shares during the last quarter. Institutional investors own 85.09% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Story: Fundamental Analysis

The Fly

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply